Clinical Trial Update: Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234) [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update reporting efficacy and long-term safety of a ragweed sublingual immunotherapy tablet (SCH 39641) in adults with ragweed-induced rhinoconju…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis
• Allergic Rhinitis
• Asthma

Drugs mentioned

• Ragweed sublingual immunotherapy tablet (SCH 39641) (ragweed pollen sublingual immunotherapy tablet)

Snippet

Sponsor: ALK-Abelló A/S | Conditions: Rhinitis, Allergic, Conjunctivitis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2014-07-03